| FZD10 Protein | |
|---|---|
| Frizzled Class Receptor 10 | |
| Gene | [FZD10](/genes/fzd10) |
| UniProt ID | Q9ULW2 |
| PDB ID | — |
| Molecular Weight | 63,700 Da |
| Subcellular Localization | Plasma membrane |
| Protein Family | Frizzled receptor family (Class F) |
| Brain Expression | Cortex, hippocampus, cerebellum, spinal cord |
| Chromosome | 2q33.3 |
| Amino Acids | 662 |
| Tissue Specificity | Restricted, high in embryogenesis |
FZD10 (Frizzled-10) is the tenth member of the Frizzled family of seven-transmembrane receptors. Originally identified as a gene overexpressed in synovial sarcoma, FZD10 has emerged as an important Wnt receptor with distinct expression patterns and functional properties. Unlike other Frizzled receptors that are widely expressed in adult tissues, FZD10 exhibits restricted expression with highest levels during embryonic development and low basal expression in most adult tissues 1.
FZD10 is unique among Frizzled receptors due to its restricted tissue distribution and its association with specific disease states, particularly cancers of mesenchymal origin. In the nervous system, FZD10 plays important roles during development and has been implicated in neuronal differentiation and circuit formation.
FZD10 shares the conserved architecture of the Frizzled receptor family:
The N-terminal CRD contains the characteristic 10 conserved cysteine residues forming five disulfide bonds. This domain serves as the primary Wnt ligand-binding interface. Structural studies indicate that FZD10 CRD has distinct binding properties compared to other Frizzled receptors, with particular affinity for certain Wnt family members 2.
Key structural features:
The extracellular linker between CRD and the first transmembrane helix is relatively short in FZD10 compared to other receptors, potentially affecting ligand access to the binding site.
Seven transmembrane helices arranged in the typical Frizzled configuration:
The C-terminal tail contains:
FZD10 activates multiple downstream signaling cascades:
Upon Wnt ligand binding, FZD10 recruits Dishevelled (DVL) proteins to the cell membrane, initiating a cascade that stabilizes β-catenin. The stabilized β-catenin translocates to the nucleus and partners with TCF/LEF transcription factors to regulate target gene expression 3.
Wnt/Planar Cell Polarity (PCP)
FZD10 can activate PCP signaling through DVL, regulating cytoskeletal dynamics and cellular polarity. This pathway is particularly important during development for tissue patterning and cell migration.
Wnt/Ca²⁺ Signaling
FZD10 couples to G-proteins that stimulate intracellular Ca²⁺ release, affecting various downstream effectors including CaMKII and PKC.
FZD10 exhibits a highly restricted expression pattern:
During embryogenesis, FZD10-mediated signaling regulates:
In the developing nervous system, FZD10 contributes to:
FZD10 is frequently overexpressed in cancers, particularly those of mesenchymal origin:
| Cancer Type | FZD10 Expression | Clinical Significance |
|---|---|---|
| Synovial sarcoma | Very high (characteristic) | Diagnostic marker |
| Colorectal cancer | High | Poor prognosis |
| Breast cancer | Moderate-high | Metastasis risk |
| Pancreatic cancer | High | Treatment target |
| Gliomas | Variable | Grade-dependent |
| Osteosarcoma | High | Survival predictor |
FZD10 represents an attractive therapeutic target in FZD10-positive cancers:
While less studied than other Frizzled receptors, FZD10 has implications in neurodegeneration:
| AD Stage | FZD10 Change | Mechanism |
|---|---|---|
| Pre-clinical | ±10% | Compensation |
| Early AD | -20% | Transcriptional downregulation |
| Moderate AD | -35% | Receptor degradation |
| Advanced AD | -50% | Comprehensive loss |
The FZD10-mediated Wnt signaling cascade involves multiple steps:
FZD10 signaling is regulated by receptor trafficking:
| Process | Mechanism | Functional Effect |
|---|---|---|
| Internalization | Caveolae-dependent | Signal termination |
| Recycling | Rab11-dependent | Signal continuation |
| Degradation | Lysosomal | Receptor downregulation |
| Recycling | Endosomal | Signal modulation |
FZD10 does not function in isolation:
| Pathway | Interaction | Outcome |
|---|---|---|
| Notch | β-catenin cross-talk | Balanced neurogenesis |
| Hedgehog | Reciprocal regulation | Developmental coordination |
| BMP | Smad-independent | Synaptic plasticity |
| FGF | Co-receptor sharing | Neuronal survival |
Wnt Ligand → FZD10 → DVL → [β-catenin / PCP / Ca²⁺] → Cellular Response
| Interaction Partner | Interaction Type | Functional Consequence |
|---|---|---|
| WNT1, WNT3, WNT3A | Ligand binding | Activates canonical signaling |
| WNT5A, WNT11 | Ligand binding | Activates non-canonical signaling |
| DVL1, DVL2, DVL3 | Direct binding | Signal transduction |
| LRP5, LRP6 | Co-receptor | Enhances canonical pathway |
| DVL1 | PDZ domain | Scaffold for signaling complex |
FZD10 expression is regulated by:
| Modification | Effect |
|---|---|
| Palmitoylation | Required for Wnt binding |
| Phosphorylation | Modulates signaling |
| Ubiquitination | Receptor turnover |
| Glycosylation | Stability and trafficking |
FZD10 represents a promising target for cancer therapy due to its restricted expression pattern:
Restoring FZD10 signaling may provide neuroprotective effects: